Neurotech International (NTI.AX) Stock Price

Neurotech International Price

ASX·CLOSED
0.01
​
Market closed

Revenue has compounded at 27.5% per year over the past 10 years to 2.44 M AUD. Neurotech International's net margin stands at -433.6%, up from -3,604.6% several years earlier.

Neurotech International stock price

Access this data via the Eulerpool API

Neurotech International business model & stock analysis

Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The firm conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. The company is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD.

Frequently asked questions about Neurotech International

Converted at the current exchange rate, the Neurotech International share trades at 0.01 EUR (0.01 AUD).

The Neurotech International share (NTI.AX) is listed on 1 stock exchanges, including: ASX (NTI.AX).

The revenue cannot currently be calculated for Neurotech International.

The profit of Neurotech International is -6.54 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neurotech International is currently -2.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neurotech International stock.

The P/S cannot be calculated for Neurotech International currently.

The Eulerpool Quality Score for Neurotech International is 2/10.

The ISIN of Neurotech International is AU000000NTI9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Neurotech International is NTI.AX. The ticker symbol is used to trade Neurotech International shares on the stock exchange.

Fair ValueTerminal
0.01 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Nov 4, 2016
ISIN
AU000000NTI9
Cusip
Q6644M102
Market capitalization
18.15 M AUDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2027
-0.18
P/Ee 2028
—
P/Ee 2029
—
P/S
P/Se
6.15
EV/EBIT
—
P/B Ratio
29.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1,069.89 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.00 AUD
Net Debt / EBIT
—
Debt/Equity
0.00
Last updated Oct 5, 2026, 2:33 PM

Neurotech International Peer Group

Neurotech International Ticker

ASX · NTI.AX

Neurotech International FIGI

NTI:AU · BBG00DSXRN71NTI:AT · BBG00DSXRN99NTI:AH · BBG00DSXRNF2